Daejeon, South Korea

Eunice Eun Kyeong Kim

This inventor holds 1 USPTO granted patent. Top assignee: Lg Chemical Ltd.. Active years: 2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eunice Eun Kyeong Kim. Retrieved from https://idiyas.com/inventor/eunice-eun-kyeong-kim-s74p8f2e

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Eunice Eun Kyeong Kim: Innovator in CDK Inhibitors

Introduction

Eunice Eun Kyeong Kim is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target critical biological pathways.

Latest Patents

Eunice holds a patent for "CDK inhibitors having flavone structure." This invention relates to a novel flavone derivative, along with its pharmaceutically acceptable salt, hydrate, solvate, and isomer. The compound is recognized for its potential as an inhibitor against Cyclin Dependent Kinase (CDK). The patent also details a process for the preparation of this compound and its application in anti-cancer agents or treatments for neurodegenerative diseases.

Career Highlights

Eunice is currently employed at LG Chem Ltd., a leading chemical company known for its innovative research and development in various sectors. His work at LG Chem has positioned him at the forefront of pharmaceutical innovation.

Collaborations

Eunice has collaborated with notable colleagues, including Chang Yong Hong and Tae Sik Park, contributing to the advancement of research in his field.

Conclusion

Eunice Eun Kyeong Kim's work in developing CDK inhibitors showcases his commitment to advancing medical science and improving treatment options for serious health conditions. His contributions are invaluable to the pharmaceutical industry and the ongoing fight against cancer and neurodegenerative diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…